



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Vopratelimab

Cat. No.:	HY-P99382
CAS No.:	2039148-04-2
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Vopratelimab (JTX-2011) is a humanized immunoglobulin G1-kappa agonist monoclonal antibody that specifically binds to the Inducible CO-Stimulator of T cells (ICOS). Vopratelimab retains species cross-reactivity with affinities of 0.93 nM to hICOS, 0.46 nM to cynomolgus ICOS, 3.7 nM to rat ICOS, and 0.64 nM to mICOS. Vopratelimab has antitumor immune response ^[1] .								
In Vitro	Vopratelimab (JTX-2011; 0.001-10 µg/mL; 3 d; CD4 T cells) has the activity of activating primary human T cells, driving IFN γ , IL-17a, IL-10, IL-9, GM-CSF, TNF α , and IL-21 secretion ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
In Vivo	Vopratelimab (JTX-2011; 0.25-0.3 mg/kg; i.p.; twice a week, for 2 weeks) promotes tumor regression in the Sa1/N murine syngeneic tumor model ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
	<table border="1" style="width: 100%;"> <tr> <td style="width: 30%;">Animal Model:</td> <td>Female A/J, Balb/c and C57BL/6 mice with Sa1/N murine syngeneic tumor model^[1]</td> </tr> <tr> <td>Dosage:</td> <td>0.25-0.3 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneal injection; twice a week, for 2 weeks</td> </tr> <tr> <td>Result:</td> <td>Regressed tumor and protected long-term in the Sa1/N murine syngeneic tumor model.</td> </tr> </table>	Animal Model:	Female A/J, Balb/c and C57BL/6 mice with Sa1/N murine syngeneic tumor model ^[1]	Dosage:	0.25-0.3 mg/kg	Administration:	Intraperitoneal injection; twice a week, for 2 weeks	Result:	Regressed tumor and protected long-term in the Sa1/N murine syngeneic tumor model.
Animal Model:	Female A/J, Balb/c and C57BL/6 mice with Sa1/N murine syngeneic tumor model ^[1]								
Dosage:	0.25-0.3 mg/kg								
Administration:	Intraperitoneal injection; twice a week, for 2 weeks								
Result:	Regressed tumor and protected long-term in the Sa1/N murine syngeneic tumor model.								

REFERENCES

[1]. Hanson A, et, al. ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models. PLoS One. 2020 Sep 24;15(9):e0239595.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA